🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 16 of 55

  1. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  2. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  3. Cyclophosphamide

    Takeda

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

    phase 2 small molecule active

    1 trial

  4. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial

  5. Cyclophosphamide

    BEONE MEDICINES AUS PTY LTD

    Recurrent Transformed Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  6. Cyclophosphamide

    United Therapeutics Europe Ltd

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  7. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial

  8. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial

  9. Cyclophosphamide Doxorubicin Vincristine Lamivudine

    Taiwan Liposome Company

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  10. Cyclophosphamide+Pemetrexed+5-Fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Thyroid Gland Carcinoma

    phase 2 small molecule active

    1 trial

  11. Cyproterone acetate 5

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  12. Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig

    AstraZeneca AB

    metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. Cyramza 10 mg/ml concentrate for solution for infusion, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  14. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Leukemia

    phase 2 small molecule terminated

    1 trial

  15. Cytarabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  16. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  17. Cytarabine and Idarubicin

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  18. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  19. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  20. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial

  21. DARATUMUMAB , BORTEZOMIB , DEXAMETHASONE

    Fondazione Telethon ETS

    Relapsed or Refractory Plasmablastic lymphoma

    phase 2 small molecule active

    1 trial

  22. DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  23. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  24. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  25. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  26. DC1 Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 2 mab active

    1 trial

  27. DCC-3014, DCC-3014, DCC-3014

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  28. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  29. DCVax-Direct

    NORTHWEST BIOTHERAPEUTICS INC

    Locally Advanced Tumor

    phase 2 mab active

    1 trial

  30. DCVax-L and T Cells

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 2 mab terminated

    1 trial

  31. DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  32. DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 small molecule active

    1 trial

  33. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  34. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  35. DEXAMETHASONE , -, -, MK-1022

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 small molecule active

    1 trial

  36. DEXAMETHASONE , ENFORTUMAB VEDOTIN , -, PARACETAMOL , -, MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  37. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  38. DEXAMETHASONE, CYCLOPHOSPHAMIDE, VINCRISTINE SULFATE, METHOTREXATE, LEVETIRACETAM, Blinatumomab SC2, Blinatumomab SC1, CYTARABINE

    Amgen

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  39. DIPHENHYDRAMINE , ANAKINRA , DEXAMETHASONE , Epcoritamab, SILTUXIMAB , PREDNISOLONE , TOCILIZUMAB , PARACETAMOL , Epcoritamab

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  40. DOCETAXEL , AVELUMAB, FLUOROURACIL , OXALIPLATIN , CALCIUM FOLINATE

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  41. DOCETAXEL , Ifinatamab Deruxtecan, Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  42. DOCETAXEL , PACLITAXEL , GEMCITABINE , VINORELBINE , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , Inflectra 100 mg powder for concentrate for solution for infusion, Micofenolato de mofetil Generis 250 mg Cápsulas

    AstraZeneca AB

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  43. DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  44. DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  45. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  46. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  47. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  48. DS-1062a

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.